We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Hikma Pharmaceuticals announced Thursday that the FDA issued a complete response letter regarding the company's filing seeking approval of a generic version of GlaxoSmithKline's asthma and chronic obstructive pulmonary disease therapy Advair Diskus (fluti